iOnctura’s mission is to develop high-impact, low-disruption therapies that extend healthspan by targeting the dynamic interplay of the tumor-stroma-immune interface. The company focuses on neglected and hard-to-treat cancers, where conventional therapies often come with side effects as severe as the disease itself. Challenging the status quo, iOnctura develops more effective, less toxic treatments. Its lead programs—Rigonolisib (PI3Kd inhibitor), Cambritaxestat (autotaxin inhibitor), and IOA-359 (TGFβ inhibitor)—are in advanced clinical development, aiming to overcome resistance in both solid and hematological cancers.